Camurus ABCAMRF -3.57%79 Market Cap is $3,350.1 Mil as of Jun. 24, 2026. GuruFocus rates CAMRF with a GF Score™ of 79/100 and a GF Value™ of $83.14 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,430 Biotechnology companies, Camurus AB ranks better than 92.38% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Camurus AB's share price for the quarter that ended in Mar. 2026 was $55. Camurus AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 59.5 Mil. Therefore, Camurus AB's market cap for the quarter that ended in Mar. 2026 was $3,273.0 Mil.
Camurus AB's quarterly market cap
declined
from Sep. 2025 ($4,104.1 Mil) to Dec. 2025 ($3,987.2 Mil) and
declined
from Dec. 2025 ($3,987.2 Mil) to Mar. 2026 ($3,273.0 Mil).
Camurus AB's annual market cap
increased
from Dec. 2023 ($1,213.2 Mil) to Dec. 2024 ($2,988.5 Mil) and
increased
from Dec. 2024 ($2,988.5 Mil) to Dec. 2025 ($3,987.2 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Camurus AB's Enterprise Value for Today is $2,959.0 Mil.
Camurus AB (OTCPK:CAMRF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Camurus AB Market Cap Related Terms
Camurus AB Market Cap Historical Data
* Premium members only.
The historical data trend for Camurus AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Camurus AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Camurus AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Camurus AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a Market Cap of $3,350.1 Mil as of Jun. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Camurus AB and its competitors. According to the industry distribution chart, Camurus AB ranks #109 out of 1430 companies in the Biotechnology industry, placing it in the top 7.6%.
Is Camurus AB's Market Cap too high?
Camurus AB's current Market Cap is $3,350.1 Mil. The Biotechnology industry median Market Cap is 117.26. Camurus AB's value of $3,350.1 Mil is 2756.9% above this industry median. Based on the distribution chart, Camurus AB ranks #109 out of 1430 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #109 out of 1430 companies for Market Cap. This places Camurus AB in the top 8% of its industry — outperforming the majority of peers. The industry median Market Cap is 117.26. Camurus AB's value of $3,350.1 Mil is 2756.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.26, based on 1,430 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Market Cap of $3,350.1 Mil is 2756.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median Market Cap is 117.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Market Cap is $3,350.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.14, compared to a current price of $54.00 — trading 35% below its estimated fair value. The current Market Cap is $3,350.1 Mil and 2756.9% above the Biotechnology industry median of 117.26. Camurus AB's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Market Cap is $3,350.1 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $54.00 is trading 35% below its estimated GF Value™ of $83.14.
GuruFocus considers Camurus AB to be Significantly Undervalued.
Key valuation signals for CAMRF:
Market Cap: $3,350.1 Mil
GF Value™: $83.14 vs. price of $54.00 (35% below fair value)
Industry Position: 2756.9% above the Biotechnology median (#109 of 1430)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
79GF Score
Get the complete analysis for CAMRF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
